Standard BioTools (LAB) Azione Prezzo
Standard BioTools Prezzo
Il fatturato è cresciuto a un tasso composto del 14,6% annuo negli ultimi 19 anni, raggiungendo 85,33 Mio. USD. Il margine netto di Standard BioTools si attesta al -87,8%, in calo rispetto al -45,4% di alcuni anni fa. Gli analisti fissano un target di prezzo mediano di 1,58 USD, ovvero il 136,0% sopra il prezzo attuale. Su 7 analisti, 4 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Standard BioTools Prezzo delle azioni
Standard BioTools Azione e analisi azionaria
Domande frequenti sull'azione Standard BioTools
The business model of Fluidigm Corp focuses on providing innovative technologies for large-scale biological research. The company develops and sells microfluidic systems, instruments, consumables, and software solutions that enable scientists to analyze biological systems at the cellular level. Fluidigm Corp's platforms are designed to enhance workflows and deliver high-quality data for a wide range of applications, including genomics, proteomics, and single-cell analysis. By offering comprehensive and advanced solutions, Fluidigm Corp aims to empower researchers in their quest for new discoveries and deeper understanding of biological processes.
Fluidigm Corp is primarily active in the life sciences industry.
The main competitors of Fluidigm Corp in the market include companies such as Illumina, Thermo Fisher Scientific, and Agilent Technologies.
Fluidigm Corp is a renowned biotechnology company that specializes in the development and commercialization of innovative tools for life sciences research. Founded in 1999, Fluidigm Corp has consistently addressed critical challenges in various fields including genomics, proteomics, and single-cell analysis. The company's cutting-edge microfluidic technologies enable researchers to gain insights into biological systems with higher precision, efficiency, and cost-effectiveness. With a commitment to advancements in medical diagnostics, drug discovery, and personalized medicine, Fluidigm Corp continues to revolutionize the way researchers analyze and understand complex biological processes.
Fluidigm Corp has achieved significant milestones throughout its history. Some key accomplishments include the development and commercialization of innovative microfluidic solutions for life sciences research and clinical diagnostics. The company's revolutionary biomarker detection technology, CyTOF®, has gained widespread recognition for its ability to provide high-resolution single-cell analysis. Additionally, Fluidigm Corp has expanded its product portfolio by introducing high-throughput genotyping and gene expression systems, empowering researchers to unlock valuable insights into complex biological processes. The company's dedication to scientific excellence and ongoing innovation has helped establish Fluidigm Corp as a pioneering force in the field of microfluidics and life sciences.
Fluidigm Corp is primarily present in countries and regions across the globe. With a strong international presence, the company operates in key markets such as North America, Europe, Asia Pacific, and Latin America. Fluidigm Corp's cutting-edge technologies and innovative solutions have gained recognition and adoption worldwide, allowing it to serve customers and partners in various industries and research fields. From its headquarters in South San Francisco, California, Fluidigm Corp has expanded its reach, establishing offices, collaborations, and customer relationships in numerous countries and regions, solidifying its position as a global leader in pioneering microfluidic technologies and scientific advancements.
Fluidigm Corp represents a set of values and corporate philosophy centered around innovation, collaboration, and scientific advancement. With a focus on developing and commercializing transformative technologies, Fluidigm Corp strives to empower researchers and clinicians to make groundbreaking discoveries. The company's dedication to precision and accuracy in their microfluidic systems is evident in their commitment to providing customers with high-quality tools for genomic research, single-cell analysis, and mass cytometry. With a customer-centric approach, Fluidigm Corp aims to drive advancements in the fields of life sciences and healthcare by enabling deeper insights and accelerating discoveries.
Gli analisti fissano attualmente un prezzo obiettivo medio di 1,58 USD per l’azione Standard BioTools (mediana: 1,58 USD), pari a +136,0 % rispetto all’ultimo prezzo. Il consenso si basa su 7 giudizi di analisti.
6 analisti valutano attualmente l’azione Standard BioTools: 4 raccomandano l’acquisto, 2 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Standard BioTools ricavi pari a 82,50 Mio. USD e un utile per azione di -0,10 USD.
Convertita al tasso di cambio attuale, l’azione Standard BioTools quota 0,60 EUR (0,67 USD).
L’azione Standard BioTools (LAB) è quotata su 5 borse, tra cui: NASDAQ (FLDM), SIX (Zürich) (FLB.SW), Frankfurt (FLB.F), München (FLB.MU), Düsseldorf (FLB.DU).
Fluidigm is a biotechnology company that develops innovative technology platforms and products for the analysis of single cells, genomics, and proteomics. The company was founded in 1999 and is headquartered in San Francisco, California. Fluidigm offers products and solutions for the study of single cells and cellular processes. The technology platforms include single-cell genomics, single-cell proteomics, and microfluidic systems. These platforms allow researchers to analyze and investigate individual cells. Fluidigm has a wide range of products that can be grouped into three main categories: gene expression, genotyping, and proteomics. Gene expression products are specifically designed for the analysis of single cells, including the C1 system and Biomark HD technology. The Biomark HD system is Fluidigm's flagship product and is used by researchers worldwide for comprehensive analysis of gene expression profiles. Fluidigm's genotyping product line is primarily used in the pharmaceutical industry and includes assays and chips that enable scientists to study individual genes in the human body. The assays are delivered by the EP1 platform, which performs highly precise genotyping processes and saves resources and time. Fluidigm's proteomics platform allows researchers to analyze proteins and proteome chains in single cells. The company offers a wide range of products, including chips, assays, and kits that detect the identity and concentration of proteins based on mass spectrometry. Fluidigm distributes its products worldwide and serves a broad customer base, including leading pharmaceutical and biotech companies, academic institutions, government agencies, and research laboratories. Fluidigm's business model is based on two core strategies, namely technology innovation and market penetration. The company continuously invests in research and development to remain at the forefront of its technology areas. This has resulted in a broad patent portfolio and a growing customer base. Fluidigm's market penetration strategy focuses on selling products to a variety of customers, including academic institutions, government agencies, and companies. The company has built a distribution infrastructure to sell its products worldwide and provide excellent customer support. In summary, Fluidigm is a biotechnology company that develops and sells innovative technology platforms and products for the analysis of single cells, genomics, and proteomics. The business model is based on technology innovation and market penetration strategy to sell its products worldwide and expand its customer base.
Il attesa fatturato di Standard BioTools ammonta a 82,50 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Standard BioTools ammonta a -38,46 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Standard BioTools è attualmente -6,71. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Standard BioTools.
Il rapporto prezzo/fatturato (P/S) di Standard BioTools è attualmente 3,13. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Standard BioTools.
Il Quality Score AlleAktien per Standard BioTools è 2/10.
L'ISIN di Standard BioTools è US34385P1084. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Standard BioTools è A0RADJ. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Standard BioTools è LAB. Con questo simbolo di borsa vengono negoziate le azioni Standard BioTools in borsa.
Azione Standard BioTools
Gruppo di pari di Standard BioTools
Standard BioTools Ticker
Standard BioTools FIGI
Altre metriche e analisi di Standard BioTools in Deep Dive.
La nostra analisi azionaria dell'azione Standard BioTools include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Standard BioTools. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: